Number of pages: 100 | Report Format: PDF | Published date: January 20, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
According to the deep-dive market assessment study by Growth Plus Reports, the global metastatic breast cancer market was valued at US$ 17 billion in 2021 and is expected to register a revenue CAGR of 9.8% to reach US$ 39.43 billion by 2030.
Metastatic Breast Cancer Market Fundamentals
Breast cancer is one of the most common forms of cancer and has been a major health concern for many years. With the advancements in technology, there have been significant changes in the treatment and diagnosis of breast cancer. According to medical terminology, advanced/metastatic breast cancer is a type of cancer that has spread from the breast to other vital organs, such as bones, lungs, liver, or brain. It is also called distant recurrence breast cancer, as it occurs when breast cancer cells travel away from the original tumor in the breast to other parts of the body through the lymphatic system or bloodstream.
According to the American Cancer Society, the number of women in the U.S. diagnosed with metastatic breast cancer has increased from 12,000 in 1975 to 40,000 in 2017. This is due to advancements in screening technologies that allow earlier cancer detection and diagnosis. Additionally, most women live longer with breast cancer, increasing possibilities of metastatic cancer.
Treatment for metastatic breast cancer can vary depending on the type and stage of cancer. However, common treatments include chemotherapy, radiation therapy, and surgery. Clinical trials are available to explore new treatment options in some cases. Chemotherapy and radiation therapy are the most frequently recommended treatments for metastatic breast cancer. Both therapies aid in reducing tumor growth. On the other hand, hormone therapy is the most effective treatment solution, as it helps in slowing down the proliferation of cancer cells.
Metastatic Breast Cancer Market Dynamics
The global metastatic breast cancer market is expected to register high revenue growth during the forecast period owing to increase in global awareness and development of novel therapies and medications for metastatic breast cancer. Due to the fast-paced business culture and rise of working from home after COVID-19, the level of workplace stress has escalated. Additionally, sedentary lifestyles have contributed to several health issues. These factors have resulted in breast cancer cases, increasing the demand for breast cancer treatments. Lack of exercise, stressful daily schedule, and denial of health problems contribute to the rise in breast cancer cases.
Rising rates of metastatic breast cancer have paved the way for new treatments such as tumor-agnostic therapy, HER2-targeted therapy, ovarian suppression, whole-brain radiation therapy, immunotherapy, stereotactic radiosurgery, and fractionated stereotactic radiation therapy. These factors are aiding in the revenue growth of the market.
To provide new drugs and treatment methods (such as blood tests for tumor markers) for the disease, numerous breast cancer therapeutics market players are increasing investments in drug discovery and development activities. Rise in investments in R&D activities and increase in cancer diagnostics awareness campaigns are expected to boost revenue growth in the market significantly.
On the other hand, lack of effectual medicines and side effects associated with these treatments are likely to constrain the growth of the global metastatic breast cancer market revenue in the next few years. Moreover, high costs of treating metastatic breast cancer are anticipated to limit market revenue growth to some extent.
Metastatic Breast Cancer Market Ecosystem
The global metastatic breast cancer market has been analyzed from three perspectives, such as treatment type, end-user, and region.
Metastatic Breast Cancer Market by Treatment Type
Based on the treatment type, the global metastatic breast cancer market is segmented into chemotherapy, biologically targeted therapy, radiation therapy, hormone therapy, and breast surgery.
The biologically targeted therapy segment accounts for the largest revenue share of the global metastatic breast cancer market. This is due to technological developments, ability of the therapy to blend with other medications, and emergence of tailored approach to improve clinical outcomes. Various molecules in targetable pathways, such as epidermal growth factor receptor (EGFR), poly (adenosine diphosphate-ribose) polymerase (PARP), and cyclin-dependent kinase 4/6 (CDK4/6), are now included in the scope of targeted medicines due to ongoing clinical trials.
The hormone therapy segment is expected to gain a significant revenue share of the global market during the forecast period. This can be attributed to rise in the adoption of this treatment type for premenopausal women to slow down the multiplication of cancer cells.
Metastatic Breast Cancer Market by End-user
Based on the end-user, the global metastatic breast cancer market is segmented into hospitals, clinics, and others.
The hospitals segment accounts for the largest share in the global metastatic breast cancer market due to the rising number of hospitals in developing countries, availability of a wide range of technologies for treatment and procedures (usage of monoclonal antibodies), and availability of different metastatic breast cancer treatment drugs (small molecule inhibitors) in hospital setups.
Metastatic Breast Cancer Market by Region
Based on the region, the global metastatic breast cancer market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
North America dominates the global metastatic breast cancer market in terms of revenue share. Several countries in North America, such as the U.S., are taking initiatives to organize breast cancer patient awareness campaigns. These factors are expected to support the rapid growth of the North America breast cancer market during the forecast period. The demand for metastatic breast cancer therapy is expected to increase in North America due to rising prevalence of cancer. Additionally, strategic developments, such as launch of therapies and acquisitions and mergers among players, are fueling revenue growth in the regional market.
The market in Asia Pacific is expected to grow at the fastest revenue CAGR during the forecast period. This can be ascribed to rising breast cancer prevalence and increasing geriatric population in this region.
The market in Europe is projected to represent a significant revenue share due to technological advancements and high prevalence of diseases in this region.
Metastatic Breast Cancer Market Competitive Landscape
The prominent players operating in the global metastatic breast cancer market are:
Metastatic Breast Cancer Market Strategic Developments
The global metastatic breast cancer market is expected to register a revenue CAGR of 9.8% during the forecast period.
F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., Novartis AG, GlaxoSmithKline Plc, and Eli Lilly and Company are among the key players operating in the global metastatic breast cancer market.
The targeted therapy segment accounts for the largest revenue share of the global metastatic breast cancer market.
Asia Pacific is expected to register a significant revenue share of the global market during the forecast period.
The global metastatic breast cancer market was valued at US$ 17 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain